Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report.

Q1 Medicine
CNS Oncology Pub Date : 2023-09-01 Epub Date: 2023-07-25 DOI:10.2217/cns-2023-0005
Mason J Webb, William G Breen, Nadia N Laack, Konstantinos Leventakos, Jian L Campian, Ugur Sener
{"title":"Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report.","authors":"Mason J Webb,&nbsp;William G Breen,&nbsp;Nadia N Laack,&nbsp;Konstantinos Leventakos,&nbsp;Jian L Campian,&nbsp;Ugur Sener","doi":"10.2217/cns-2023-0005","DOIUrl":null,"url":null,"abstract":"<p><p>Leptomeningeal disease (LMD) remains a challenging condition with a dismal prognosis. In this case study, we report partial response of LMD in a patient with metastatic large cell neuroendocrine carcinoma following treatment with proton craniospinal irradiation (CSI), bevacizumab, and pembrolizumab. Two years after the initial diagnosis, he presented with LMD. He underwent proton CSI with bevacizumab followed by combination therapy with pembrolizumab and bevacizumab. He had a partial disease response with progression-free survival after LMD diagnosis of 4.6 months. He unfortunately developed pembrolizumab induced hypophysitis, after which he experienced rapid neurologic clinical progression. Overall, this novel combination led to a durable partial response which warrants prospective evaluation.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/b5/cns-12-101.PMC10410687.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2023-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Leptomeningeal disease (LMD) remains a challenging condition with a dismal prognosis. In this case study, we report partial response of LMD in a patient with metastatic large cell neuroendocrine carcinoma following treatment with proton craniospinal irradiation (CSI), bevacizumab, and pembrolizumab. Two years after the initial diagnosis, he presented with LMD. He underwent proton CSI with bevacizumab followed by combination therapy with pembrolizumab and bevacizumab. He had a partial disease response with progression-free survival after LMD diagnosis of 4.6 months. He unfortunately developed pembrolizumab induced hypophysitis, after which he experienced rapid neurologic clinical progression. Overall, this novel combination led to a durable partial response which warrants prospective evaluation.

Abstract Image

Abstract Image

Abstract Image

贝伐单抗和pembrolizumab质子颅脊髓照射治疗软脑膜疾病:一例报告。
瘦素血症(LMD)仍然是一种具有挑战性的疾病,预后不佳。在这项病例研究中,我们报道了一名转移性大细胞神经内分泌癌患者在接受质子颅脊髓照射(CSI)、贝伐单抗和pembrolizumab治疗后,LMD的部分反应。在最初诊断两年后,他出现了LMD。他接受了贝伐单抗质子CSI,随后接受了pembrolizumab和贝伐单抗联合治疗。在LMD诊断后,他出现了部分疾病反应,无进展生存期为4.6个月。不幸的是,他患上了pembrolizumab诱导的垂体炎,之后他经历了快速的神经临床进展。总的来说,这种新颖的组合导致了持久的部分反应,值得进行前瞻性评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CNS Oncology
CNS Oncology Medicine-Neurology (clinical)
CiteScore
3.80
自引率
0.00%
发文量
12
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信